DENVER, Aug. 28 /PRNewswire/ -- Myogen, Inc., a biopharmaceutical company
focused on discovering, developing and commercializing drugs for the treatment
of cardiovascular disorders, announced today that it has filed a registration
statement on Form S-1 with the Securities and Exchange Commission for an
initial public offering of shares of its common stock.
The underwriters of the offering will be Credit Suisse First Boston and
JPMorgan, acting as joint book-running managers, and CIBC World Markets and
Lazard, acting as co-managers. The number of shares to be offered and the
price range for the offering have not yet been determined.
The offering will be made only by means of a prospectus. When available,
a copy of the preliminary prospectus relating to the offering may be obtained
from the prospectus department of either Credit Suisse First Boston LLC (One
Madison Avenue, New York, New York 10010; 212-325-2580) or J.P. Morgan
Securities Inc. (One Chase Manhattan Plaza, Floor 5B, New York, New York
10081; 212-552-5164).
A registration statement relating to these securities has been filed with
the Securities and Exchange Commission but has not yet become effective.
These securities may not be sold nor may offers to buy be accepted prior to
the time the registration statement becomes effective. This press release
shall not constitute an offer to sell, or the solicitation of, an offer to buy
nor shall there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or
jurisdiction.
About Myogen
Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of small molecule therapeutics for the
treatment of cardiovascular disorders. Myogen currently markets one product
in Europe for the treatment of acute decompensated heart failure and is
developing three product candidates for three distinct cardiovascular
indications. We also conduct a target and drug discovery research program
focused on the development of disease-modifying drugs for the treatment of
chronic heart failure and related cardiovascular disorders. Please visit our
website at http://www.myogen.com .
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Joseph L. Turner, Chief Financial Officer,
+1-303-464-5222, joe.turner@myogen.com , or Derek K. Cole,
Director, Investor Relations, +1-303-464-3986,
derek.cole@myogen.com , both of Myogen, Inc.
|
